Pharmacodynamic application of L-dopa in cardiogenic shock.
D000818:Animals; D001011:Aorta; D001794:Blood Pressure / Q000187:drug effects; D003326:Coronary Circulation / Q000187:drug effects; D004295:Dihydroxyphenylalanine / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D004285:Dogs; D005260:Female; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles; D007668:Kidney / Q000098:blood supply; D008297:Male; D008638:Mesenteric Arteries; D008642:Mesenteric Veins; D010643:Phenoxybenzamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D012770:Shock, Cardiogenic / Q000188:drug therapy*; D013997:Time Factors; D014655:Vascular Resistance / Q000187:drug effects
D010643:Phenoxybenzamine; D004295:Dihydroxyphenylalanine; D011433:Propranolol